Keywords
How to Cite
Abstract
The efficiency of a course of melatonin use (for 1 month) was studied in 15 old (69,9±1,8 years) patients with type 2 diabetes mellitus. The influence of melatonin on carbohydrate and lipid metabolism was studied, as well as the functional state of endothelium, blood viscosity, arterial blood pressure. The use of melatonin (3 mg at 21:00 daily) led to an improvement of carbohydrate metabolism: the levels of glucose and insulin 2 hours after glucose-tolerance test
were decreased, and the square under the glucose-insulin curve was significantly decreased. Melatonin use also led to an improvement of lipid metabolism (statistically significant decrease in TG and LDLP levels), improvement of microvessels endothelium function (the volume speed of skin circulation was significantly increased) and blood rheological properties (statistically significant decrease in blood viscosity and erythrocytes aggregation index). The data of
this investigation appear to be a rationale for melatonin use in elderly people with type 2 diabetes mellitus.
References
Edinburgh: Churchill Livingstone, 1971, 345-360.
2. Bojkova B., Markova M., Ahlersova E. et al. Metabolic effects of prolonged melatonin administration and short-term fasting in laboratory rats // Acta Veterinaria Brno. 2006, 75, N 1, 21-32.
3. Peschke E., Peschke D., Hammer T., Csemus V. Influence of melatonin and serotonin on glucose-stimulated insulin release from perifused rat pancreatic islets in vitro // J. Pineal Res. 1997, 23, 156-163.
4. Peschke E., Fauteck J.D., Musshoff U. et al. Evidence for a melatonin receptor within pancreatic islets of neonate rats: functional, autoradiographic, and molecular investigations // J. Pineal Res. 2000, 28, N 3, 156-164.
5. Rasmussen D.D., Boldt B.M., Wilkinson C.W. et al. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin and plasma insulin to youthful levels // Endocrinology. 1999, 140, 1009-1012.
6. Kemp D.M., Ubeda M., Habener J.F. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in
incretin-mediated cell function by sensitization of cAMP signalling // Mol. Cell. Endocrinol. 2002, 191, 157-166.
7. Peschke E., Bach A.G., Villbaurer E. Parallel signaling pathways of melatonin in the pancreatic beta-cell // J. Pineal Res. 2006, 40, N 2, 184-191.
8. Peschke E., Frese T., Chankiewitz E. et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and
an increased pancreatic melatonin-receptor status // J. Pineal Res. 2006, 40, N 2, 135-143.
9. Contreras-Alcantara S., Baba K., Tosini G. Removal of melatonin receptor type 1 induces insulin resistance in the mouse // Obesity (Silver Spring). 2010, 18, N 9, 1861-1863.
10. Nishida S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus // Endocrine. 2005, 27, N 2, 131-135.
11. Гончарова Н.Д., Хавинсон В.Х., Лапин Б.А. Пинеальная железа: возрастная патология (механизмы и коррекция). СПб.: Наука, 2007. 168 с. (Goncharova N.D., Khavinson V.Kh., Lapin B.A. Pineal gland: age pathology (mechanisms and correction. St.Petersburg: Nauka, 2007. 168 p.)
12. Winiarska K., Fraczyk T., Malinska D. et al. Melatonin attenuates diabetes-induced oxidative stress in rabbits //J. Pineal Res. 2006, 40, N 2, 168-176.
13. Диденко В.А. Метаболический синдром Х: история вопроса и этиопатогенез // Лабораторная медицина. 1999, № 2, 49-57. (Didenko V.A. Metabolic syndrome X: history of the question and etiopathogenesis // Lab. Medicine. 1999, N 2, 168-176.)
14. Шилов А.М., Мельник М.В. Артериальная гипертония и реологические свойства крови. М.: «БАРС». 2005. 206 c. (Shilov A.M., Melnik M.V. Arterial
hypertension and rheological properties of blood. Moscow: “BARS”. 2005. 206 p.
15. Bakker W., Eringa E.C., Sipkema P., van Hinsbergh V.W. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity
// Cell Tissue Res. 2009, N 335, 165-189.